1Department of Biochemistry, Vels Institute of Science and Technology and Advance Studies, Chennai, Tamil Nadu, India
2Cancer Genetics and Molecular Biology Laboratory, Department of Bioinformatics, Science Campus, Alagappa University, Karaikudi, Tamil Nadu, India
*Corresponding Author E-mail: dr.langeswaran@gmail.com
Online published on 30 April, 2020.
The present study absorbed the anti-cancer activity of diosmin at 50, 100, 150, 200 μM/ml for 24h of treatment on dose dependent manner. Group II animals were administrated 0.01% NDEA to induce primary liver carcinoma. Cancer bearing experimental animals were treated orally with the drug diosmin at the dosage level of 200 mg per kg/bodyweight for 28 successive days.
Diosmin treatment on HepG2 cells constrains nearly half of the cell population and proliferation at the dose of 100 μM/ml and in vivo experimental studies showed remarkable repossession in biochemical and morphological characteristics. These results summarizes that both in vivo and in vitro anti-carcinogenic activity of diosmin could be an outstanding flavonoid in the treatment of HCC because of its therapeutic and pharmacological properties.
Diosmin, Flavonoids, N-nitrosodiethylamine, SEM, HCC, HepG2 cells
